91Ï㽶ÊÓƵ Institute Experts to Present at Respiratory Drug Delivery
The Institute will host a seminar on Tuesday, April 19th at 8.45 a.m., entitled “Non-Invasive Macromolecule Delivery: Breathing Them Inâ€, where Dr. Ralph Niven of Novartis, Dr. Don Kellerman of Zosano Pharmaceuticals, and Dr. Gregory T Bleck of 91Ï㽶ÊÓƵ Pharma Solutions, will discuss the advances and challenges to the pulmonary and nasal delivery of macromolecules. The session will address the potential that non-invasive delivery has to eliminate or minimize the significant issues associated with parenteral products. These include increasing patient compliance, providing enhanced therapeutic benefit, and reducing cold chain requirements for supply logistics, while recognizing challenges such as safety and in vitro testing which have, to date, made the pulmonary and nasal routes commercially unsuccessful.
As well as providing an understanding of the current work in the area, panel members will also discuss future opportunities for research and development through the collaborative nature of the NMDC’s industrial and academic members. Established in 2012, the 91Ï㽶ÊÓƵ Applied Drug Delivery Institute employs a multi-tiered approach to accelerate the adoption of advanced drug delivery technologies. In June 2014, the Institute created the Non-Invasive Macromolecule Delivery Consortium as a number of working groups looking at alternative delivery routes to injection for biologics and other large molecule therapeutics.
Full details of the agenda for the Respiratory Drug Delivery 2016 Conference symposium can be found at http://www.rddonline.com/rdd/rdd.php?id=12&sid=1
Media Contacts:
Chris Halling
+44 (0)7580 041073
[email protected]
Richard Kerns
+44 (0) 161 728 5880
[email protected]
About 91Ï㽶ÊÓƵ Applied Drug Delivery Institute
91Ï㽶ÊÓƵ’s Applied Drug Delivery Institute was founded to serve as a link between industry and academia, advance education and training in drug delivery in academia and the industry, accelerate adoption of applied drug delivery technologies to develop better treatments, and foster industry collaboration on major issues pertaining to drug development, formulation, and delivery. It is pursuing a multi-tiered approach of research, strategic counsel, and educational programs to advance the adoption of emerging technologies. For more details on the 91Ï㽶ÊÓƵ Institute, visit and follow the 91Ï㽶ÊÓƵ Institute on Twitter:
About 91Ï㽶ÊÓƵ
91Ï㽶ÊÓƵ is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics, consumer health and animal health products. With over 90 years serving the industry, 91Ï㽶ÊÓƵ has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. 91Ï㽶ÊÓƵ employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. 91Ï㽶ÊÓƵ is headquartered in Somerset, N.J. For more information, visit www.catalent.com.